Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy

The new era of personalized medicine, which integrates the uniqueness of an individual with respect to the pharmacokinetics and pharmacodynamics of a drug, holds promise as a means to provide greater safety and efficacy in drug design and development. Personalized medicine is particularly important in oncology, whereby most clinically used anticancer drugs have a narrow therapeutic window and exhibit a large interindividual pharmacokinetic and pharmacodynamic variability. This variability can be explained, at least in part, by genetic variations in the genes encoding drug metabolizing enzymes, transporters, or drug targets. Understanding of how genetic variations influence drug disposition and action could help in tailoring cancer therapy based on individual’s genetic makeup. This review focuses on the pharmacogenomics of drug metabolizing enzymes and drug transporters, with a particular highlight of examples whereby genetic variations in the metabolizing enzymes and transporters influence the pharmacokinetics and/or response of chemotherapeutic agents.

[1]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.

[2]  Shufeng Zhou.  Clinical pharmacogenomics of thiopurine S-methyltransferase. , 2006, Current clinical pharmacology.

[3]  Akane Kawamura,et al.  Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. , 2008, Toxicology.

[4]  I Meineke,et al.  The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin , 2009, Clinical pharmacology and therapeutics.

[5]  J. Schuetz,et al.  Role of ABCG2/BCRP in biology and medicine. , 2006, Annual review of pharmacology and toxicology.

[6]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[7]  M. Oshimura,et al.  FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA , 2005, Drug Metabolism and Disposition.

[8]  P. Soulié,et al.  Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance , 2006, Molecular Cancer Therapeutics.

[9]  D. Schrenk,et al.  A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. , 2002, Pharmacogenetics.

[10]  Shigeki Sugiura,et al.  ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS , 2005, Drug Metabolism and Disposition.

[11]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[13]  S. Venitt,et al.  The metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. , 1998, Carcinogenesis.

[14]  J Verweij,et al.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[16]  Brian Tomlinson,et al.  OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.

[17]  J. Schellens,et al.  Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications , 2000, Annals of the New York Academy of Sciences.

[18]  T. Ishikawa,et al.  A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. , 2003, The Biochemical journal.

[19]  Mikko Niemi,et al.  Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.

[20]  Michael M Gottesman,et al.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. , 2009, Biochimica et biophysica acta.

[21]  D. Townsend,et al.  Glutathione S-transferase polymorphisms: cancer incidence and therapy , 2006, Oncogene.

[22]  R. Callaghan,et al.  Role of GSH in Estrone Sulfate Binding and Translocation by the Multidrug Resistance Protein 1 (MRP1/ABCC1)* , 2006, Journal of Biological Chemistry.

[23]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[24]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[25]  J. Robert,et al.  Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. , 1996, Cancer research.

[26]  D. Grant,et al.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. , 1990, DNA and cell biology.

[27]  T. Ishikawa,et al.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design , 2005, Naturwissenschaften.

[28]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[30]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[31]  L. Wienkers,et al.  Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[32]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[33]  J. Verweij,et al.  Effect of ABCG2 genotype on the oral vioavailability of topotecan , 2005, Cancer biology & therapy.

[34]  A. V. van Herwaarden,et al.  The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.

[35]  P. Vreken,et al.  Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. , 1997, European journal of cancer.

[36]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[37]  D. Kroetz,et al.  Functional Implications of Genetic Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) , 2004, Pharmaceutical Research.

[38]  K. Kawakami,et al.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.

[39]  H. Kroemer,et al.  VARIABLE EXPRESSION OF MRP2 (ABCC2) IN HUMAN PLACENTA: INFLUENCE OF GESTATIONAL AGE AND CELLULAR DIFFERENTIATION , 2005, Drug Metabolism and Disposition.

[40]  Fanfan Zhou,et al.  Molecular Insights into the Structure–Function Relationship of Organic Anion Transporters OATs , 2006, Pharmaceutical Research.

[41]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[42]  K. Nooter,et al.  Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib , 2004, Cell cycle.

[43]  A. Guo,et al.  Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[44]  R. Kerb.  Implications of genetic polymorphisms in drug transporters for pharmacotherapy. , 2006, Cancer letters.

[45]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[46]  P. Parte,et al.  OXIDATION OF TAMOXIFEN BY HUMAN FLAVIN-CONTAINING MONOOXYGENASE (FMO) 1 AND FMO3 TO TAMOXIFEN-N-OXIDE AND ITS NOVEL REDUCTION BACK TO TAMOXIFEN BY HUMAN CYTOCHROMES P450 AND HEMOGLOBIN , 2005, Drug Metabolism and Disposition.

[47]  M. Hidalgo,et al.  Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. , 2006, Journal of the National Cancer Institute.

[48]  Hyeong-Seok Lim,et al.  Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. , 2008, Lung cancer.

[49]  H. Takane,et al.  The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications , 2004, Clinical pharmacokinetics.

[50]  Lang Li,et al.  Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Y. Cheung,et al.  Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. , 2005, British journal of clinical pharmacology.

[52]  Abstr Act,et al.  SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study , 2008 .

[53]  N. Malats,et al.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses , 2005, The Lancet.

[54]  Heinz Bönisch,et al.  Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3 , 2002, British journal of pharmacology.

[55]  M R Gaab,et al.  Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. , 2004, Clinical neuropathology.

[56]  W. Ichikawa,et al.  Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen , 2006, Clinical Cancer Research.

[57]  T. Edwards,et al.  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. , 2004, Pharmacogenomics.

[58]  R. Tukey,et al.  Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. , 2002, Molecular pharmacology.

[59]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[60]  P. Neuvonen,et al.  Pharmacokinetics of metformin after intravenous and oral administration to man , 1979, European Journal of Clinical Pharmacology.

[61]  J. Shin,et al.  Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.

[62]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[63]  R. Kim,et al.  Pharmacogenomics of the OATP and OAT families. , 2004, Pharmacogenomics.

[64]  R. Franke,et al.  Pharmacogenetics of the organic anion transporting polypeptide 1A2. , 2009, Pharmacogenomics.

[65]  S. Fuqua,et al.  An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. , 1997, Cancer research.

[66]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[67]  Shashi Amur,et al.  Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.

[68]  J. Clegg,et al.  The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. , 2003, Blood cells, molecules & diseases.

[69]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.

[70]  T. Sakaeda.  MDR1 genotype-related pharmacokinetics: fact or fiction? , 2005, Drug metabolism and pharmacokinetics.

[71]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[72]  Y. Maehara,et al.  Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[74]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. , 1993, Cancer research.

[75]  Vered Stearns,et al.  CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance , 2010, Current oncology reports.

[76]  Mikko Niemi,et al.  Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[77]  T. Mizutani.  PM Frequencies of Major CYPs in Asians and Caucasians , 2003, Drug metabolism reviews.

[78]  Kaoru Kobayashi,et al.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells , 2005, Pharmacogenetics and genomics.

[79]  R. Remmel,et al.  Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer , 2006, Oncogene.

[80]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[81]  C. Guillemette.  Pharmacogenomics of human UDP-glucuronosyltransferase enzymes , 2003, The Pharmacogenomics Journal.

[82]  J. Verweij,et al.  Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. , 2005, Pharmacogenomics.

[83]  L. Carey,et al.  CYP2D6 and tamoxifen: DNA matters in breast cancer , 2009, Nature Reviews Cancer.

[84]  N. Božina,et al.  Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk , 2009, Arhiv za higijenu rada i toksikologiju.

[85]  G. Wen,et al.  Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. , 2005, Kidney international.

[86]  Sharon Marsh,et al.  Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype , 2004, Clinical pharmacology and therapeutics.

[87]  Michel Eichelbaum,et al.  Interindividual variability of canalicular ATP‐binding‐cassette (ABC)–transporter expression in human liver , 2006, Hepatology.

[88]  Hassane Izzedine,et al.  Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. , 2006, The Journal of infectious diseases.

[89]  Bradford Ld.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[90]  K. Kondo,et al.  Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8 , 2002, Journal of Human Genetics.

[91]  G. Suarez-Kurtz.  Pharmacogenomics in admixed populations. , 2007, Trends in pharmacological sciences.

[92]  M. Komajda,et al.  A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination , 2005, Pharmacogenetics and genomics.

[93]  R. Kim.  MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. , 2002, Pharmacogenetics.

[94]  H. Lenz,et al.  Thymidylate synthase gene variations: predictive and prognostic markers , 2009, Molecular Cancer Therapeutics.

[95]  S. Cole,et al.  Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). , 2003, Biochemistry.

[96]  Jing Li,et al.  Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients , 2007, Cancer biology & therapy.

[97]  C. Falany,et al.  Pharmacogenetics of human cytosolic sulfotransferases , 2006, Oncogene.

[98]  J. Agúndez.  Polymorphisms of human N-acetyltransferases and cancer risk. , 2008, Current drug metabolism.

[99]  M. Salto‐Tellez,et al.  Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  F. Ali-Osman,et al.  Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. , 2007, Current opinion in pharmacology.

[102]  S. Dehal,et al.  CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. , 1997, Cancer research.

[103]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.

[104]  Yuichi Sugiyama,et al.  Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal Efflux Mediated by Breast Cancer Resistant Protein (BCRP/ABCG2) , 2005, Pharmaceutical Research.

[105]  R. Kim,et al.  Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). , 2008, Drug metabolism reviews.

[106]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[107]  Balram Chowbay,et al.  Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients , 2006, Pharmacogenetics and genomics.

[108]  S. Shibutani,et al.  Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen. , 1997, Chemical research in toxicology.

[109]  D. Keppler,et al.  Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.

[110]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[111]  H. Glatt,et al.  Pharmacogenetics of soluble sulfotransferases (SULTs) , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[112]  F. Chang,et al.  Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis , 2002, Hepatology.

[113]  J. Verweij,et al.  Role of pharmacogenetics in irinotecan therapy. , 2006, Cancer letters.

[114]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[115]  T. Ishikawa,et al.  Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2 , 2007, Cancer science.

[116]  R. Glashan,et al.  ROLE OF N-ACETYLTRANSFERASE PHENOTYPES IN BLADDER CARCINOGENESIS: A PHARMACOGENETIC EPIDEMIOLOGICAL APPROACH TO BLADDER CANCER , 1982, The Lancet.

[117]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[118]  J. Nortier,et al.  Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan , 2005, Clinical Cancer Research.

[119]  J. Robert,et al.  Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. , 1998, The Journal of pharmacology and experimental therapeutics.

[120]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[121]  Taylor J. Maxwell,et al.  Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes , 2008, Clinical Cancer Research.

[122]  E. Gillam,et al.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[123]  H. McLeod,et al.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. , 1996, The Journal of clinical investigation.

[124]  B. Bonanni,et al.  Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  B. Hamilton,et al.  Analyses of 5′ regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3) , 2006, Journal of Human Genetics.

[126]  H. Kotani,et al.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 , 2004, International journal of cancer.

[127]  M. Hiratsuka,et al.  Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. , 2003, British journal of clinical pharmacology.

[128]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[129]  S. Groshen,et al.  A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. , 2004, Pharmacogenetics.

[130]  Charles Swanton,et al.  Genetic prognostic and predictive markers in colorectal cancer , 2011, Nature Reviews Cancer.

[131]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[132]  I. Song,et al.  Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. , 2008, Drug metabolism and pharmacokinetics.

[133]  Jukka Corander,et al.  CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure , 2007, Pharmacogenetics and genomics.

[134]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[135]  Hyeong-Seok Lim,et al.  Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[137]  J. Nezu,et al.  Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. , 2002, The Journal of pharmacology and experimental therapeutics.

[138]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[139]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[140]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  Michel Roger,et al.  CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS , 2005, Drug Metabolism and Disposition.

[142]  P. Vreken,et al.  A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency , 1996, Journal of Inherited Metabolic Disease.

[143]  Sharon Marsh,et al.  Irinotecan pathway genotype analysis to predict pharmacokinetics. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[144]  R. Kim,et al.  Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.

[145]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[146]  R. Kim,et al.  Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. , 2009, Molecular pharmaceutics.

[147]  K. Omura.  Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines , 2003, International Journal of Clinical Oncology.

[148]  C. Kitagawa,et al.  Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity , 2005, Pharmacogenetics and genomics.

[149]  W. Ichikawa,et al.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer , 2003, British Journal of Cancer.

[150]  G. Kullak-Ublick,et al.  Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. , 2008, Pharmacogenomics.

[151]  J. Scheys,et al.  Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.

[152]  T. Ishikawa,et al.  Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport , 2006, Molecular Pharmacology.

[153]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[154]  L. Hutchins,et al.  Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. , 2002, Journal of the National Cancer Institute.